GlassScriptPhysician profile
Victoria E Panelli-Ramery
NPI 1467440891
$12,548.78
in general payments reported to CMS, 2019-2025
73 companies · $2,861 in 2025
The $2,861 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $872 · 2020: $691 · 2021: $1,367 · 2022: $1,034 · 2023: $2,523 · 2024: $3,201 · 2025: $2,861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,507 · Education: $77.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,507.24 |
| Education | $77.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,073.54 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $855.80 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $747.86 | 2019-2025 | Tecvayli, Darzalex, Rybrevant |
| E.R. Squibb & Sons, L.L.C. | $740.21 | 2019-2025 | Opdivo, Opdualag, Augtyro |
| Astrazeneca Pharmaceuticals LP | $728.54 | 2019-2025 | Enhertu, Imfinzi, Calquence |
| Daiichi Sankyo INC. | $699.82 | 2019-2025 | Enhertu, Injectafer |
| Pfizer INC. | $670.64 | 2019-2025 | |
| Celgene Corporation | $515.53 | 2020-2025 | Reblozyl, Pomalyst, Opdivo |
| Incyte Corporation | $362.43 | 2019-2025 | Monjuvi, Jakafi |
| Eisai INC. | $334.87 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $300.96 | 2019-2025 | Onivyde, Somatuline Depot |
| Bayer Healthcare Pharmaceuticals INC. | $298.50 | 2019-2025 | |
| Gilead Sciences, INC. | $286.74 | 2021-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $283.65 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| Amgen INC. | $273.38 | 2019-2024 | Blincyto, Kyprolis, Nplate |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victoria Panelli-Ramery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.